MILLIPLEX<sup>®</sup> multiplex and SMC<sup>®</sup> high-sensitivity immunoassay detection of Alzheimer’s disease biomarkers in human cerebrospinal fluid, plasma, and serum
MILLIPORESIGMA SPONSORED CONTENT

MILLIPLEX® multiplex and SMC® high-sensitivity immunoassay detection of Alzheimer’s disease biomarkers in human cerebrospinal fluid, plasma, and serum

High-sensitivity immunoassay detection of Alzheimer’s disease biomarkers

The need for blood-based biomarkers of Alzheimer’s disease (AD) has driven a search for novel candidates; however, limitations exist in identifying blood-based biomarkers due to the sensitivity of standard immunoassay methodologies. High-sensitivity immunoassay technologies, such as SMC® technology enables the measurement of low-abundant proteins in a variety of biofluids and creates opportunities for the identification of novel biomarkers. This application note explores the capabilities of SMC® technology for quantifying AD biomarkers in diverse sample types in combination with using commercially-available MILLIPLEX® Neuroscience kits using CSF, plasma, and serum from AD samples and healthy controls. Download now to learn more.

Download Now

    Please fill out the information below to download the content. If you are already registered, or have requested a quote before, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

    • By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.